PHARMA

PHARMA

Pharmaceutical Hydrogenation Membrane in Norway

Catalytic hydrogenation is a critical step in active pharmaceutical ingredient (API) synthesis. Norway leverages its vast hydropower resources for green hydrogen production, targeting maritime fuel cells and industrial decarbonization.

Market Context

Norway

Policy

Norwegian Hydrogen Strategy

H₂ Target

Maritime hydrogen fuel and industrial decarbonization

1

Cities

4

Industries

Ultra-Clean Hydrogen Source

Electrolytic hydrogen from water splitting is inherently free of carbon monoxide, sulfur, and hydrocarbon impurities that can poison precious metal hydrogenation catalysts used in API manufacturing.

GMP-Compatible On-Site Generation

On-site electrolysis provides a controlled, traceable hydrogen source that simplifies GMP documentation and qualification versus multi-sourced delivered gas.

Batch-Flexible Operation

Pharmaceutical manufacturing operates in batches. IONZERA's high wettability supports start-stop operation, generating hydrogen only when hydrogenation reactors require it.

Pharmaceutical Hydrogenation in Norway’s Hydrogen Market

Norway leverages its vast hydropower resources for green hydrogen production, targeting maritime fuel cells and industrial decarbonization. The country's maritime sector is an early mover in hydrogen-powered vessels, while the oil and gas industry is pivoting toward hydrogen and CCS technologies.

IONZERA supports Norway's hydropower-to-hydrogen pathway with high-efficiency membranes that maximize hydrogen output from Norway's low-cost renewable electricity.

Maritime HydrogenHydropower-to-H2Oil & Gas TransitionAmmonia Shipping
3x

Lower Resistance

20%

Thinner Profile

PERFORMANCE ADVANTAGE

Why IONZERA for Pharmaceutical Hydrogenation in Norway

Electrolytic hydrogen from water splitting is inherently free of carbon monoxide, sulfur, and hydrocarbon impurities that can poison precious metal hydrogenation catalysts used in API manufacturing.

Shipping & Logistics

Air freight from India to Oslo in 6-8 business days.

Area Resistance

3x LOWER
Area Specific Resistance ComparisonIONZERA0.09-0.1 Ω·cm²Zirfon0.30 Ω·cm²00.10.20.3 Ω·cm²~3x Lower

Thickness

20% THINNER
Membrane Thickness ComparisonIONZERA350-410 μmZirfon500 μm500 μm scale20-30%thinnerThinner membrane = More compact stacks= Higher power density

Pharmaceutical Hydrogenation Membrane in Norway Cities

Frequently Asked Questions

Why choose IONZERA for pharmaceutical hydrogenation in Norway?

IONZERA delivers 3x lower ionic resistance than Zirfon, making it ideal for pharmaceutical hydrogenation applications in Norway. IONZERA supports Norway's hydropower-to-hydrogen pathway with high-efficiency membranes that maximize hydrogen output from Norway's low-cost renewable electricity.

Is IONZERA suitable for maritime hydrogen applications in Norway?

Yes. IONZERA membranes support on-site hydrogen production via alkaline electrolysis for maritime fuel cell systems. The membrane's high efficiency helps produce hydrogen at competitive costs for vessel refueling.

Ready to Start

Request Pharmaceutical Hydrogenation Samples for Norway

Contact G-Hexa for IONZERA pharmaceutical hydrogenation membrane samples, technical specifications, and volume pricing for Norway-based projects.

Request Sample